OncoMatch/Clinical Trials/NCT06914037
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Is NCT06914037 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies CHT101 for peripheral t-cell lymphoma.
Treatment: CHT101 — Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD70 positive (positive)
Disease stage
Required: Stage IIB AND ABOVE (FOR CTCL)
stage ≥IIB with disease involving two or more compartments or single-compartment disease with large-cell transformation (for CTCL); measurable disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy
Peripheral T cell lymphoma...who have failed ≥1 line of systemic therapy
Must have received: systemic therapy
Cutaneous T cell lymphoma...who have failed ≥2 lines of systemic therapies
Must have received: systemic therapy containing anti-CD20 antibody and anthracyclines
Aggressive B cell lymphoma who are refractory or relapsed post ≥2 lines of systemic therapies which contain anti-CD20 antibody and anthracyclines
Must have received: systemic therapy containing anti-CD20 antibody
Indolent B cell lymphoma who are refractory or relapsed post ≥2 lines of systemic therapies which contain anti-CD20 antibody
Must have received: systemic therapy containing BTK inhibitor and BCL-2 inhibitor
Chronic lymphocytic leukemia (CLL) who are refractory or relapsed post ≥2 lines of systemic therapies which contain BTK inhibitor and BCL-2 inhibitor
Cannot have received: CD70-targeting agent
Prior treatment with CD70-targeting agents
Cannot have received: CAR-T cell therapy
Prior treatment with CAR-T or other cellular/gene therapies
Cannot have received: cellular/gene therapy
Prior treatment with CAR-T or other cellular/gene therapies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06914037 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD70-targeting agent, CAR-T cell therapy, cellular/gene therapy disqualifies patients from enrollment.
Does this trial require CD70?
Yes, CD70 positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIB AND ABOVE (FOR CTCL) is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages